Laparoscopic Roux-en-Y gastric bypass (LRYGB)
ProcedureLaparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
NCT Number: NCT01784848
Phase 3, unicentric, randomized clinical trial, with allocation concealment and intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y Gastroplasty to decrease the prescription of antihypertensive drugs maintaining normal levels of blood pressure, decrease systemic arterial blood pressure and other risk factors for cardiovascular events compared to clinical treatments of patients with arterial hypertension.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
Randomization:
The randomization list is electronically generated through specific software. A block randomization is conducted with varying block sizes at the rate of 1:1. Confidentiality of the randomization list is ensured by the central automated randomization system, through the Internet, available 24 hours a day (ACT Clinic - Sistema de Estudos Clínicos do IEP HCor).
Blinding Scheme:
Because the study involves a surgical procedure, investigators and patients cannot be blind for treatment allocated to patients.
Roux-en-Y Gastroplasty Patients allocated to surgical treatment will be admitted to the hospital to be subjected to a Roux-en-Y gastric bypass with a biliopancreatic loop of 100cm and a alimentary limb of 150cm.
Antihypertensive Treatment:
The treatment of hypertension will be standardized for all study patients. Prescribed drugs will include preferably a renin-angiotensin blocking system drug and a calcium channels blocker, except if these are contraindicated or the patient has achieved good blood pressure control using other drugs prior to study recruitment. Other drugs can be added at discretion of the attending investigator to achieve a target blood pressure of 130 x 80 mmHg. Patients are treated individually for the other associated comorbidities. Obesity treatment in the control group includes dietary advice, motivation for the practice of physical activities, and drug treatments for diabetes and dyslipidemias if applicable.
Laboratory tests and other exams:
All patients will be subjected to the following measurements throughout the study:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
Time frame: 12 months
Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (<140x90 mmHg), in 12 months.
Time frame: 12, 24, 36, 48 and 60 months
Evaluate the efficacy of Roux-en-Y Gastric Bypass on the reduction of the number of antihypertensive drugs, maintaining a controlled blood pressure (<140x90 mmHg).
Time frame: 12, 24, 36, 48 and 60 months
Change on systemic blood pressure assessed by ambulatory blood pressure monitoring (ABPM).
Time frame: 12, 24, 36, 48 and 60 months
Change on central blood pressure augmentation index and pulse wave velocity as measured by SphygmoCor device
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline in systolic blood pressure
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline in diastolic blood pressure
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on weight loss
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on BMI
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on waist circumference
Time frame: 12, 24, 36, 48 and 60 months
Change from baseline on fasting plasm glucose level, HbA1c and insulin resistance
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on LDL-cholesterol level
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on HDL-cholesterol level
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on triglycerides levels
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on uric acid levels
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline on ultra-sensitive CRP levels
Time frame: 12, 24, 36, 48 and 60 months
Absolute change from baseline of cardiovascular risk calculated by Framingham Score
Time frame: 12, 24, 36, 48 and 60 months
Change on heart anatomy as evaluated by echocardiogram
Time frame: 12, 24, 36, 48 and 60 months
Change on sleep quality as evaluated by polysomnography
Time frame: At any time during the study period
Describe the main adverse events
Hospital do Coracao
Other
Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.
Acronym: GATEWAY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07363447
Arterial Hypertension, Cardiovascular Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT03710473
Cardiovascular Diseases, Hypertension
Bern, Switzerland
View Trial DetailsNCT04396405
Cardiovascular Diseases, Hypertension
Ankara, Turkey (Türkiye)
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial Details